How quickly does Alport syndrome progress?

Although Alport syndrome may not be considered one of the most severe types of CKD, the condition can cause a much more rapid progression to end-stage kidney disease (ESKD).3-7

Alport syndrome is a severe form of CKD

Patients with Alport syndrome are at risk of rapidly progressing to ESKD.3-7

ADPKD=autosomal dominant polycystic kidney disease.
*Based on hypothetical data comparisons and calculations.

Keep Alport syndrome from going undetected

The severity of Alport syndrome makes early detection critical. Considering Alport syndrome when patients present with declining glomerular filtration rate—particularly when accompanied by hematuria and/or a family history of CKD/AS—may help accurately identify the condition sooner.1,2,8-11

Confirming an Alport syndrome diagnosis sooner is possible with genetic testing

Behind the Mystery:
Progression

Watch this video to learn how the progression of Alport syndrome varies from patient to patient and how the condition can be monitored.

Highlight Alport syndrome by recognizing the following signs:

  • Persistent Hematuria
  • Underlying Inflammation
  • Reduced GFR
  • Family History of CKD or Alport Syndrome

Test your knowledge on
Alport Syndrome

Never miss an update

Ongoing research continues to reveal previously unknown information about Alport syndrome. Join our mailing list for periodic updates about the condition.

Genetic testing for Alport syndrome and several other rare forms of chronic kidney disease is more accessible than ever before. Find out the eligibility requirements for no-charge genetic testing through KIDNEYCODE.


1. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV a345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93(5):1045-1051. 2. Savige J, Colville D, Rheault M, et al. Alport syndrome in women and girls. Clin J Am Soc Nephrol. 2016;11(9):1713-1720. 3. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. 4. Wright J, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431. 5. Torres V, Chapman A, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930-1942. 6. Reata announces positive topline year one results from pivotal phase 3 cardinal study of bardoxolone methyl in patients with Alport syndrome. News release. Reata Pharmaceuticals, Inc. November 11, 2019. Accessed December 19, 2019. https://www.reatapharma.com/press-releases/reata-announces-positive-topline-year-one-results-from-pivotal-phase-3-cardinal-study-of-bardoxolone-methyl-in-patients-with-alport-syndrome/?releaseyear=2019. 7. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19-62. 8. Nestor JG, Groopman EE, Gharavi AG. Towards precision nephrology: the opportunities and challenges of genomic medicine. J Nephrol. 2018;31(1):47-60. 9. Gross O, Kashtan CE, Rheault MN, et al. Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol Dial Transplant. 2017;32(6):916-924. 10. Groopman E, Goldstein D, Gharavi A. Diagnostic utility of exome sequencing for kidney disease. Reply. N Engl J Med. 2019;380(21):2080-2081. 11. Arora P. Chronic kidney disease. Medscape. Updated August 1, 2019. Accessed September 16, 2020. https://emedicine.medscape.com/article/238798-overview.
References: